Health
Study shows brilacidin strongly inhibits SARS-CoV-2 in laboratory cell lines – News-Medical.Net
A recent study by US researchers reveals that brilacidin, a small synthetic molecule with peptide-like properties, exerts potent in vitro antiviral activity against…
A recent study by US researchers reveals that brilacidin, a small synthetic molecule with peptide-like properties, exerts potent in vitro antiviral activity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – both as a standalone treatment and in combination with FDA-approved remdesivir. The study is currently available on the bioRxiv* preprint server.
SARS-Cov-2, the pathogen and causative agent of coronavirus disease 19 (COVID-19), has been responsible for more than 1.2…
-
Noosa News22 hours agoMajor crash on Gateway Motorway snarls morning commute
-
Business23 hours agoUp 34% this year, can Challenger shares keep rising according to Macquarie?
-
Business19 hours agoThis ASX 200 mining stock is eyeing the lithium throne
-
General22 hours agoA stitch in crime • Inside Story